By The Life Science Report
Source: Streetwise Reports 01/05/2019
The background and justification for the deal was covered in an H.C. Wainwright & Co. report.
GENFIT SA (GNFT:PA; GNFTF:OTC.MKTS) signed a license agreement with Covance, LabCorp’s clinical drug research and development division, for it to expand access to GENFIT’s proprietary biomarker diagnostic test for nonalcoholic steatohepatitis (NASH), analyst Ed Arce reported in a Jan. 3 research report. The deal terms have not been released.
However, Arce pointed out, the companies made clear the main purpose of the arrangement is to gain further proof GENFIT’s NIS4 is a valid, preferred way to identify and characterize NASH patients and to yield new insights into how NASH develops through Covance’s deployment of it in the clinical research space via its central laboratories.
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
“This agreement represents a critical step in both validating and ultimately commercializing a simple, noninvasive alternative to liver biopsy for screening and identifying the most appropriate patients for therapeutic intervention,” Arce commented, adding that liver biopsy currently is the current test for diagnosing NASH and fibrosis stage.
Arce highlighted that accurate diagnosis of NASH represents an unmet need recognized by the FDA. “There are simply not enough specialists to enable biopsy as a widely available test,” he noted, and the failure rate of diagnostic NASH through clinical trial screening is above 50%. Further, liver biopsy is expensive, “highly invasive,” and has significant associated risks.
GENFIT anticipates, relayed Arce, that in the 20202021 time frame it will receive FDA approval and a CE mark for its NIS4 serum biomarker for NASH and will launch the test across the United States and Europe.
H.C. Wainwright & Co. has a Buy rating and a 105 per share price target on GENFIT, whose stock is currently trading at around 18.15 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from H.C. Wainwright & Co., Genfit S.A., First Take, January 3, 2019
I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analysts household has a financial interest in the securities of Avenue Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of December 31, 2018 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Galectin Therapeutics, Inc.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The Firm or its affiliates did not receive compensation from GENFIT S.A for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in GENFIT S.Aas of the date of this research report.
( Companies Mentioned: GNFT:PA; GNFTF:OTC.MKTS,